Faculty Publications
As of August 2017, this database is no longer being updated. For the most current publications from the faculty, students, and staff of Touro University, please check our institutional repository, Touro Scholar, and email any questions or publication submissions to touro.scholar@touro.edu.
Total number of publications: 7,082
Enter a faculty name:
or browse faculty by school:
Administrative Offices
Graduate Schools
Health Sciences
Lander Colleges
Law Center
New York School of Career and Applied Studies (NYSCAS)
Touro University System
New York Medical College (NYMC)
Touro University California
Touro University Nevada
Citrome, L. (2016). Rosacea and dementia: Relative vs. absolute effect sizes. International Journal of Clinical Practice, 70(6), 428-429. doi:10.1111/ijcp.12834
Citrome, L. (2016). Schizophrenia relapse, patient considerations, and potential role of lurasidone. Patient Preference and Adherence, 10, 1529-1537. doi:10.2147/PPA.S45401
Citrome, L. (2016). The grey literature is far from drab. International Journal of Clinical Practice, 70(10), 790. doi:10.1111/ijcp.12899
Citrome, L. (2016). Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 196, 225-233. doi:10.1016/j.jad.2016.02.042
Citrome, L. (2016). What's in a name? Use of brand vs. generic drug names. International Journal of Clinical Practice, 70(1), 3-4. doi:10.1111/ijcp.12772
Citrome, L. (2016). Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? Evidence-Based Mental Health, 19(2), e6. doi:10.1136/eb-2015-102143
Citrome, L. (2016). Zika and you. International Journal of Clinical Practice, 70(3), 181-182. doi:10.1111/ijcp.12793
Citrome, L., & Ketter, T. A. (2013). When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. International Journal of Clinical Practice, 67(5), 407-411. doi:10.1111/ijcp.12142
Citrome, L., & Ketter, T. A. (2015). Number needed to treat can be helpful: A response to Andrade. The Journal of Clinical Psychiatry, 76(9), e1136-e1137. doi:10.4088/JCP.15lr10001
Citrome, L., & Ketter, T. A. (2015). Pharmacotherapy for bipolar depression: Comparative efficacy and acceptability is in the eye of the beholder. Evidence-Based Mental Health, 18(3) [Article 88]. doi:10.1136/eb-2015-102062
Citrome, L., & Ketter, T. A. (2016). NNT and NNH remain helpful in evidence-based medicine. The British Journal of Psychiatry, 209(3), 262-263. doi:10.1192/bjp.209.3.262b
Citrome, L., & Magnusson, K. (2014). Paging Dr Cohen, Paging Dr Cohen... An effect size interpretation is required STAT!: visualising effect size and an interview with Kristoffer Magnusson. International Journal of Clinical Practice, 68(5), 533-534. doi:10.1111/ijcp.12435
Citrome, L., & Volavka, J. (2014). The psychopharmacology of violence: Making sensible decisions. CNS Spectrums, 19(5), 411-8. doi:10.1017/S1092852914000054
Citrome, L., & Volavka J (2015). Preventing violence in patients with schizophrenia. Current Treatment Options in Psychiatry, 2(2), 182-191. doi:10.1007/s40501-015-0039-4
Citrome, L., Collins, J. M., Nordstrom, L., Rosen, E. J., Baker, R., Nadkarni, A., & Kalsekar, I. (2013). Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics. Journal of Clinical Psychiatry, 74(12), 1199-1206. doi:10.4088/JCP.13m08642
Citrome, L., Du, Y., Risinger, R., Stankovic, S., Claxton, A., Zummo, J., . . . Ehrich, E. W. (2016). Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia. International Clinical Psychopharmacology, 31(2), 69-75. doi:10.1097/YIC.0000000000000106
Citrome, L., Durgam, S., Lu, K., Ferguson, P., & Laszlovszky, I. (2016). The effect of cariprazine on hostility associated with schizophrenia: Post hoc analyses from 3 randomized controlled trials. The Journal of Clinical Psychiatry, 77(1), 109-115. doi:10.4088/JCP.15m10192
Citrome, L., Eramo, A., Francois, C., Duffy, R., Legacy, S. N., Offord, S. J., . . . Rohman, P. (2015). Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatric Disease and Treatment, 11, 3095-3104. doi:10.2147/NDT.S91917
Citrome, L., Goldberg, J. F., & Portland, K. B. (2013). Placing transdermal selegiline for major depressive disorder into clinical context: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders, 151(2), 409-417. doi:10.1016/j.jad.2013.06.027
Citrome, L., Gommoll, C. P., Tang, X., Nunez, R., & Mathews, M. (2015). Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: Post-hoc analyses of a phase IV trial. International Clinical Psychopharmacology, 30(2), 75-81. doi:10.1097/YIC.0000000000000056
Citrome, L., Johnston, S., Nadkarni, A., Sheehan, J. J., Kamat, S. A., & Kalsekar, I. (2014). Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and medicaid insured patients newly initiating atypical antipsychotics. Current Drug Safety, 9(3), 227-235. doi:10.2174/1574886309666140601211551
Citrome, L., Kalsekar, I., Baker, R. A., & Hebden, T. (2014). A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Current Medical Research and Opinion, 30(8), 1629-1641. doi:10.1185/03007995.2014.908280
Citrome, L., Kalsekar, I., Guo, Z., Laubmeier, K., & Hebden, T. (2013). Diagnoses associated with use of atypical antipsychotics in a commercial health plan: A claims database analysis. Clinical Therapeutics, 35(12), 1867-1875. doi:10.1016/j.clinthera.2013.09.006
Citrome, L., Kamat, S. A., Sapin, C., Baker, R. A., Eramo, A., Ortendahl, J., . . . Gutierrez, B. (2014). Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of Medical Economics, 17(8), 567-576. doi:10.3111/13696998.2014.917089
Citrome, L., Kando, J., Bliss, C., & Herman, B. (2016). Relationships between the clinical global impressions scale, binge eating days, and the Yale-Brown obsessive compulsive scale modified for binge eating in adults with moderate to severe binge eating disorder in two phase 3 studies. Neuropsychopharmacology, 41(S1), S350-S351.
